Five Under-the-Radar Stocks With Catalysts Already in Motion — Across AI Defense, Space, Longevity, Gold, and Post-Quantum Security

Avaí Bio, formerly Avant Technologies, completed its rebrand in February to focus on genetically modified cellular platforms targeting longevity and diabetes. The company initiated GMP production of a Master Cell Bank for its α-Klotho anti-aging therapy Klothonova in early March, a joint venture with Austrianova. Avaí Bio is scheduled to present latest data at the Second Annual Klotho Conference in September alongside Dr.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.